摘要
目的:研究慢性前列腺炎/慢性盆腔疼痛综合征(CP/CPPS)4种药物治疗方案的成本-效果。方法:140例CP/CPPS患者随机分为4组,分别给予百炎净片+坦索罗辛缓释胶囊(A组)、米诺环素微丸+阿夫唑嗪缓释片(B组)、罗红霉素片+甲磺酸多沙唑嗪控释片(C组)、左氧氟沙星片+特拉唑嗪片(D组),运用药物经济学方法进行成本-效果分析。结果:A、B、C、D组成本分别为268·8元、641·8元、660·8元、666·4元;有效率分别为71·4%、91·4%、88·6%、91·4%;成本-效果比分别为3·76、7·02、7·46、7·29;B、C、D组相对于A组的增量成本-效果比分别为18·65、22·79、19·88。结论:CP/CPPS的治疗成本分为抗生素部分与α1受体阻滞药部分,医师应根据患者的以往用药情况、经济状况、身体健康状况等作出最佳选择。
OBJECTIVE： To study the cost - effectiveness of 4 dose regimens in treating chrorlic prostatitis / chronic pelvic cavity pain syndrome （CP/CPPS）, METHODS： A total of 140 patients with CP/CPPS were randomly divided into 4 groups. Baiyanjing tablets and tamsulosin hydrochloride modified release capsules were administered for Group A; minocycline micro pills and alfuzosin retard tablets for Group B; rexithromycin tablets and doxazosin mesylate controlled release tablets for Group C; and levofloxaein tablets and terazosin tablets for Group D. The cost - effectiveness analysis was performed using pharmacoeconomics. RESULTS. The costs for the Group A, B, C and D were 268.8 yuan, 641,8 yuan, 660.8 yuan and 666.4 yuan, respectively. The effective rates were 71.4%, 91.4%, 88.6% and 91.4%, respectively, The cost - effectiveness ratios were 3.76, 7.02, 7.46 and 7.29, respectively. The incremental cost - effectiveness ratios of Group B, C and D were 18.65, 22.79 and 19.88, respectively as against Group A, CONCLUSION： The treatment cost of CP/ CPPS was composed of 2 parts： antibiotics α1- receptor blockers. Doctors should make an optimum choice based on patients＇ previous medication, economic status and physical condition, etc,
出处
《中国药房》
CAS
CSCD
北大核心
2006年第4期271-273,共3页
China Pharmacy
